Loss of RRM2 has been reported to induce cell cycle arrest, cell senescence and SASP phenotypes, and the RRM2 inhibitor COH29 has been proven to exert notable antitumor effects in prostate cancer cells [53]. This evidence concerns the gene RRM2 and prostate carcinoma.